Proactive Research analyst Emma Ulker presents her research on Tiziana Life Sciences (LON:TILS) (NASDAQ:TLSA) and their advancing therapeutic pipeline.
She says the focus is on the lead immunotherapy Foralumab, a fully-human anti-CD3 monoclonal antibody (mAb) being developed for oral and nasal routes of administration, providing novel approaches in treating severe inflammatory and autoimmune disease.
Top line data from a recent trial in COVID-19 patients conducted in Brazil demonstrate exciting potential to reduce lung inflammation, both compared to control, and to Foralumab combined with Dexamethasone.